Brookline Capital Management Stock Recommendations and Price Targets

This is a list of recent ratings by Brookline Capital Management.

Date	Company Name	Action	Current Price	Price Target	Rating	Impact on Share Price
5/15/2024	DARE Daré Bioscience	Upgrade	$0.00	$3.00	Hold ➝ Buy	Low
4/17/2024	DARE Daré Bioscience	Downgrade	$0.00		Buy ➝ Hold	N/A
4/5/2024	IMUX Immunic	Reiterated Rating	$1.00	$10.00	Buy	Low
3/19/2024	FUSN Fusion Pharmaceuticals	Downgrade	$22.00		Buy ➝ Hold	N/A
3/4/2024	ATE Antibe Therapeutics	Downgrade	C$0.00		Buy ➝ Hold	N/A
3/4/2024	ATBPF Antibe Therapeutics	Downgrade	$0.00		Buy ➝ Hold	Low
2/28/2024	ANVS Annovis Bio	Downgrade	$8.00	$9.00	Buy ➝ Hold	Low
1/25/2024	OTLK Outlook Therapeutics	Upgrade	$8.00	$31.40	Hold ➝ Buy	Low
12/19/2023	CYCC Cyclacel Pharmaceuticals	Downgrade	$2.00		Buy ➝ Hold	Low
12/7/2023	HEPA Hepion Pharmaceuticals	Downgrade	$1.00		Buy ➝ Hold	Low
12/4/2023	ONCT Oncternal Therapeutics	Upgrade	$9.00	$40.00	Hold ➝ Buy	Low
11/30/2023	LNTH Lantheus	Initiated Coverage	$80.00	$100.00	Buy	Low
11/15/2023	SQZB SQZ Biotechnologies	Downgrade	$0.00		Buy ➝ Hold	Low
11/10/2023	ANVS Annovis Bio	Reiterated Rating	$8.00	$35.00	Buy	Low
10/30/2023	GNLX Genelux	Upgrade	$4.00		Hold ➝ Buy	Low
10/17/2023	EYEN Eyenovia	Initiated Coverage	$1.00	$8.00	Buy	Low
10/12/2023	EDSA Edesa Biotech	Reiterated Rating	$5.00	$57.00	Buy ➝ Buy	Low
9/6/2023	PROC Procaps Group	Downgrade	$3.00	$4.50	Buy ➝ Hold	Low
8/30/2023	OTLK Outlook Therapeutics	Downgrade	$8.00		Buy ➝ Hold	Low
8/14/2023	ATBPF Antibe Therapeutics	Reiterated Rating	$0.00		Buy	Low
8/11/2023	BCEL Atreca	Downgrade	$0.00		Buy ➝ Hold	Low
6/5/2023	BLPH Bellerophon Therapeutics	Downgrade	$0.00		Buy ➝ Hold	Low
4/3/2023	ONCT Oncternal Therapeutics	Downgrade	$9.00		Buy ➝ Hold	Low
3/9/2023	ONCT Oncternal Therapeutics	Reiterated Rating	$9.00		Buy	Low
2/14/2023	DARE Daré Bioscience	Reiterated Rating	$0.00		Buy	Low
2/13/2023	FUSN Fusion Pharmaceuticals	Reiterated Rating	$22.00		Buy	Low
1/31/2023	HEPA Hepion Pharmaceuticals	Reiterated Rating	$1.00		Buy	Low
1/20/2023	BCEL Atreca	Reiterated Rating	$0.00		Buy	Low
1/12/2023	ECOR electroCore	Reiterated Rating	$7.00		Buy	N/A
12/7/2022	CWBR CohBar	Downgrade	$1.00		Buy ➝ Hold	Low
11/14/2022	IMNN Imunon	Reiterated Rating	$1.00		Buy	Low
10/3/2022	CWBR CohBar	Reiterated Rating	$1.00		Buy	Low
10/3/2022	ADIL Adial Pharmaceuticals	Reiterated Rating	$2.00		Buy	Low
10/3/2022	LSTA Lisata Therapeutics	Reiterated Rating	$3.00		Buy	Low
10/3/2022	IMNN Imunon	Reiterated Rating	$1.00		Buy	Low
10/3/2022	DRMA Dermata Therapeutics	Reiterated Rating	$4.00		Buy	Low
10/3/2022	VXRT Vaxart	Reiterated Rating	$1.00		Buy	Low
10/3/2022	EDSA Edesa Biotech	Reiterated Rating	$5.00		Buy	Low
10/3/2022	MNPR Monopar Therapeutics	Reiterated Rating	$1.00		Buy	Low
10/3/2022	CYCC Cyclacel Pharmaceuticals	Reiterated Rating	$2.00		Buy	Low
10/3/2022	OTLK Outlook Therapeutics	Reiterated Rating	$8.00		Buy	Low
8/15/2022	ATE Antibe Therapeutics	Reiterated Rating	C$0.00		Buy	N/A
8/10/2022	ARCT Arcturus Therapeutics	Reiterated Rating	$30.00		Buy	Low
8/8/2022	BCEL Atreca	Reiterated Rating	$0.00		Buy	Low
6/30/2022	ATBPF Antibe Therapeutics	Reiterated Rating	$0.00		Buy	N/A
5/18/2022	VERU Veru	Boost Price Target	$1.00	$29.00 ➝ $31.00	Buy ➝ Buy	Medium
4/4/2022	BLPH Bellerophon Therapeutics	Lower Price Target	$0.00	$26.00 ➝ $19.00		Low
3/10/2022	VRCA Verrica Pharmaceuticals	Reiterated Rating	$9.00		Buy	Medium
3/7/2022	NTLA Intellia Therapeutics	Upgrade	$26.00	$91.00	Hold ➝ Buy	High
2/14/2022	CRSP CRISPR Therapeutics	Reiterated Rating	$56.00	$143.00	Buy	High
2/14/2022	NTLA Intellia Therapeutics	Reiterated Rating	$26.00		Buy	Low
2/14/2022	CRBU Caribou Biosciences	Reiterated Rating	$3.00		Buy	Medium
2/3/2022	BCDA BioCardia	Reiterated Rating	$0.00		Buy	High
2/2/2022	FUSN Fusion Pharmaceuticals	Reiterated Rating	$22.00		Buy	Medium
2/1/2022	ICCM IceCure Medical	Reiterated Rating	$1.00		Buy	Low
1/26/2022	HEPA Hepion Pharmaceuticals	Reiterated Rating	$1.00		Buy	Low
1/19/2022	DARE Daré Bioscience	Reiterated Rating	$0.00		Buy	High
12/14/2021	PROC Procaps Group	Reiterated Rating	$3.00	$13.00	Buy	Low
10/13/2021	KYMR Kymera Therapeutics	Reiterated Rating	$35.00	$80.00	Buy	Medium
10/13/2021	ADIL Adial Pharmaceuticals	Reiterated Rating	$2.00	$300.00	Buy	High
9/21/2021	DRMA Dermata Therapeutics	Reiterated Rating	$4.00	$3,360.00	Buy	High
9/3/2021	FBRX Forte Biosciences	Reiterated Rating	$1.00		Hold	Low
8/27/2021	VERU Veru	Reiterated Rating	$1.00		Buy	Medium
8/24/2021	SCYX SCYNEXIS	Reiterated Rating	$3.00		Buy	Low
7/29/2021	BCEL Atreca	Reiterated Rating	$0.00		Buy	High
6/25/2021	CCCC C4 Therapeutics	Reiterated Rating	$6.00		Buy	High
6/23/2021	BLPH Bellerophon Therapeutics	Reiterated Rating	$0.00		Buy	Medium
6/3/2021	ATE Antibe Therapeutics	Reiterated Rating	C$0.00		Buy	N/A
6/3/2021	ATBPF Antibe Therapeutics	Reiterated Rating	$0.00		Buy	Medium
5/25/2021	MNPR Monopar Therapeutics	Reiterated Rating	$1.00		Buy	Medium